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In 2015, an outbreak of Human Immunodeficiency Virus (HIV) was identified among people who inject drugs 
(PWID) in the Greater Glasgow and Clyde (GGC) area of Scotland, an area which distributes over one million 
needles and syringes per year. This is the largest such incident in the UK for 30 years. This study provides the 
first epidemiological analysis of the impact of the outbreak on HIV prevalence trends in the population and the 
individual and environmental risk factors associated with infection.  
Methods 
Four cross-sectional anonymous bio-behavioural surveys of almost 4000 PWID attending services providing 
injecting equipment across GGC between 2011 and 2018 were analysed. Participants were recruited by trained 
independent interviewers and eligible if they had a history of injecting drug use, either current (within the past 
six months) or historical. Interviewers asked participants questions about demographics, behaviours and 
service use and to give a dried blood spot sample to test anonymously for the presence of blood-borne viruses. 
Trends in prevalence of HIV infection, risk behaviours, and intervention coverage were examined. Logistic 
regression was used to determine individual and environmental factors associated with HIV infection.  
Findings 
Between 2011-12 and 2017-18, HIV prevalence in GGC rose from 0·1% (1/927) to 4·8% (39/821) overall, and 
from 1·1% (1/87) to 10·8% (25/231) in Glasgow city centre, respectively. Over the same period, the prevalence 
of cocaine injecting in GGC rose from 16% (129/806) to 50% (291/583) overall, and from 37% (26/70) to 77% 
(117/153) in Glasgow city centre. HIV infection was more likely among PWID who had: participated in 2015-18 
versus earlier survey years (AOR 3.4, 95% CI: 1·7 to 6·7); been homeless in the past six months versus not 
homeless in the past six months (AOR 3·0, 95% CI: 1·7 to 5·0); multiple incarcerations since first began injecting 
versus low number of incarcerations (AOR 2·1, 95% CI: 1·2 to 3·7); and injected cocaine within the past six 
months versus not injected cocaine in the past six months (AOR 6·7, 95% CI: 3·8 to 12·1). Age per one-year of 
increase was also a significant factor (AOR 1·1, 95% CI: 1·0 to 1·1). Gender showed borderline significance with 
females more likely to be HIV positive than males (AOR 1·7, 95% CI: 0·9 to 3·2). 
Interpretation 
Despite high coverage of harm reduction interventions, Glasgow has experienced a rapid rise in prevalence of 
HIV among its PWID population, associated with homelessness, incarceration and a major shift to injection of 
cocaine. Robust surveillance through regular HIV testing of high risk populations is critical to ensure outbreaks 
are detected and rapid responses are informed by the best available evidence.  
Funding 




Research in context 1 
Evidence before this study 2 
People who inject drugs (PWID) are at risk of Human Immunodeficiency Virus (HIV) transmission through 3 
sharing of injecting equipment and unprotected sex. Opioid agonist therapy and needle and syringe 4 
programmes are effective in preventing HIV transmission among PWID. In recent years, a number of outbreaks 5 
of rapidly transmitting HIV infection among PWID have been observed in areas of Europe and North America 6 
where incidence has been low since the 1980’s. We searched PubMed on 1 June, 2018, with the search terms 7 
“HIV” AND “PWID” AND “Injecting” AND “outbreak” for publications from Jan 1, 2010, to May 31, 2018, 8 
restricted to English language, but with no restriction on geographical location.  9 
Added value of this study 10 
In the context of outbreaks of HIV among PWID reported globally in the last 10 years, this is the first to 11 
investigate the determinants of infection using an approach which combines both statistical power and robust 12 
survey methods applied consistently over time.  13 
Implications of all the available evidence 14 
Availability of harm reduction services is not sufficient on its own to prevent HIV outbreaks occurring among 15 
highly vulnerable populations. Increased injecting of stimulants among high risk populations potentially 16 
presents a threat to global HIV elimination strategies. Regular and robust surveillance, through HIV testing of 17 
high risk populations, is critical to ensure outbreaks are detected and rapid responses are informed by the best 18 
available evidence. 19 
Introduction 20 
People who inject drugs (PWID) are at risk of Human Immunodeficiency Virus (HIV) transmission primarily 21 
through sharing of injecting equipment,
1
 but also through unprotected sex.
2
 Internationally, there are 22 
estimated to be 15·6 million PWID of whom 17·8% are living with HIV.
3
 Prevalence of HIV among PWID is 23 
highest in Latin America (35·7%) and Eastern Europe (24·7%); Western Europe has one of the lowest 24 
prevalence rates internationally (4.5%). In recent years, a number of outbreaks of rapidly transmitting HIV 25 
infection among PWID have been observed in areas of Europe and North America where incidence has been 26 
low since the 1980’s.
4-6
 In Scotland, there are an estimated 15,000-20,000 PWID.
7-8
 Major outbreaks of HIV 27 




Since then, HIV prevention 28 
has been effective in controlling the spread of infection among PWID for over three decades, largely as a result 29 
of widespread availability of Opioid Agonist Treatment (OAT), needle and syringe programmes (NSP), and anti-30 
retroviral treatment (ART) for HIV infection. Until recently, the number of newly diagnosed HIV infections 31 
among PWID in Scotland remained stable at around 15 per year; however in 2015, the annual number rose to 32 
52. The vast majority (n=47) of these new cases were from the Greater Glasgow and Clyde (GGC) area which 33 
incorporates Glasgow, Scotland’s largest city. The outbreak has persisted with over 100 new cases identified 34 
during 2015-17. Routine viral sequence testing of the Glasgow cases identified a rarely observed HIV subtype C 35 
virus in the majority of samples.
11
 Furthermore, phylogenetic analysis revealed that this strain has not been 36 
identified outside of Scotland and that transmission was occurring rapidly.
12 37 
The current HIV outbreak in Glasgow is the first community-based outbreak among PWID in the UK for over 30 38 
years. Further, and most unusually in comparison to other recently observed outbreaks of HIV among PWID 39 
internationally, it was occurring despite the existence of a comprehensive harm reduction environment. The 40 
high proportion of women involved in the outbreak has also increased concerns regarding sexual transmission. 41 
There is an imperative to learn about the circumstances of HIV outbreaks among PWID in countries with 42 
historically low prevalence and tackle complacency in prevention if we are to maintain progress in tackling the 43 
HIV epidemic. 44 
Using data from Scotland’s decade-long national surveys of PWID,
13
 this paper aims to: (i) examine the 45 
prevalence of HIV over time among PWID in GGC and (ii) assess the individual and environmental risk factors 46 




Study design and data sources 49 
The Needle Exchange Surveillance Initiative (NESI) is a voluntary, anonymous, cross-sectional survey of PWID 50 
attending community-based services providing injecting equipment in mainland Scotland to monitor rates of 51 
blood-borne virus (BBV) infection and risk behaviours in this population.
13
 During 2008-2018, six national 52 
surveys have been undertaken, each involving a sample of approximately 2,500; GGC contributing 53 
approximately 1,000 participants per survey. Eligibility criteria are a history of injecting drug use, either current 54 
(within the past six months) or historical. Around 80% of each survey is comprised of current PWID. Trained 55 
interviewers ask participants questions about their demographics, behaviours and service use 56 
(https://www.hps.scot.nhs.uk/resourcedocument.aspx?id=5866), and to give a dried blood spot (DBS) sample 57 
to test anonymously for the presence of hepatitis C and, in some surveys, other BBVs. HIV testing was included 58 
in surveys conducted in GGC from 2011 onwards. A £5 shopping voucher is provided to individuals who 59 
complete the survey as compensation for their time. The interviews are carried out by trained researchers who 60 
obtain informed consent from all participants prior to data collection.  Ethical approval for the NESI survey was 61 
granted by the NHS West of Scotland Research Ethics Committee (REC Ref: 08/S0709/46). 62 
Outcomes 63 
In each of our three models, the outcome measure was HIV infection status, derived from laboratory testing of 64 
DBS samples using a 4
th
 generation HIV antigen/antibody combination assay.
14
 NESI sampling and laboratory 65 
testing methods have been previously described.
13  66 
Statistical analysis 67 
In total, data from 3,641 PWID recruited in GGC as part of the four NESI surveys conducted during 2011-18 68 
were available for descriptive analysis following the removal of duplicate survey participants within each 69 
survey (i.e. those who participated more than once in a particular survey) using basic identifiers (initials, 70 
gender, date of birth) and missing data.  71 
In our multivariate analysis, data from 2,712 PWID recruited in GGC as part of the four NESI surveys conducted 72 
during 2011-18 were available following the further removal of duplicate survey participants across surveys 73 
(i.e. those who took part in more than one survey) and questionnaires with insufficient or missing data. 74 
Unadjusted and adjusted logistic regression was used to identify risk factors associated with HIV.  75 
We assessed outcomes according to relevant ‘individual’ and ‘environmental’ risk factors for HIV using the 76 
work of Jolly and colleagues as a guiding definitional framework.
15
 In addition, our modelling strategy was 77 
underpinned by the widely accepted minimal criterion for sample size considerations in logistic regression 78 
analysis; ten events per variable.
16
 As our sample consisted of 69 HIV positive cases, we thus limited ourselves 79 
to a maximum of seven covariates per model. In our first model, we examined relevant individual risk factors 80 
for HIV among PWID; average weekly alcohol consumption in the past 12 months (above 14 units per week, 81 
below 14 units per week); unprotected sex (in the last six months, not in the last six months); cocaine injecting 82 
(in the last six months, not in the last six months); and injecting frequency (low frequency (less than four time 83 
per day), high frequency (4 or more times per day)). For our second model, we focussed on environmental risk 84 
factors; NESI survey year (2011-2014 (pre identification of the outbreak), 2015-2018 (post-identification of the 85 
outbreak); age at time of survey; biological sex; homelessness (in the last six months, not in the last six 86 
months); methadone status (prescribed in the last six months, not prescribed in the last six months); 87 
needle/syringe coverage per injection (<100%, 100%); and number of times in prison since first injected drugs 88 
(low number (five incarcerations or less) high number (more than 5 incarcerations)). In our third model, we 89 
combined the significant factors significant at the <10% level from the individual and environmental risk 90 
models.  91 
All analysis was conducted using SPSS v21. 92 
3 
 
Role of the funding source 93 
The funding source did not have any role in study design, data collection, analysis, or interpretation, in the 94 
writing of the report, or in the decision to submit this work for publication. The corresponding author had full 95 
access to all the data in the study and had final responsibility for the decision to submit for publication. 96 
Results 97 
In the overall GGC sample, HIV prevalence rose from 0·1% (95% CI: 0·0-0·6) in 2011-12 to 4·8% (95% CI: 3·4-98 
6·2) in 2017-18 (Figure 1). This was mainly driven by increases in Glasgow City where HIV prevalence rose from 99 
1·1% (95% CI: 0·2-6·2) in 2011-12 to 10·8% (95% CI: 7·4-15·5) in 2017-18 (Table 1).  100 
INSERT FIGURE 1 101 
For those testing HIV negative on DBS between 2011 and 2018, the average age of participants in the surveys 102 
significantly increased (Table 1). Other significant, but less linear, changes in trends were observed among 103 
those drinking, on average, above the recommended UK Government guidelines for weekly alcohol 104 
consumption (14 units for men and women). The proportion of male participants was largely stable across 105 
surveys, as was the proportion of participants with a high number of incarcerations and recent experience of 106 
homelessness. Prevalence of Hepatitis C also remained fairly stable across surveys, although prevalence 107 
amongst those surveyed in Glasgow city centre was typically higher than those recruited outside of the city 108 
centre. 109 
Among those who tested positive for HIV infection on DBS between 2011 and 2018, the majority were male, 110 
although a third of HIV positive participants in 2017-18 were female. Similarly, the proportion with excessive 111 
alcohol consumption rose sharply in 2017-18. In addition, those testing positive for HIV appeared to have had 112 
a high number of incarcerations and to have had recent experience of homelessness. Prevalence of Hepatitis C 113 
among HIV infected cases was also considerably higher than in the HIV negative sample. 114 
INSERT TABLE 1 115 
In the HIV negative sample, a significant downward trend was observed over time for those who reported 116 
having unprotected sex in the past six months. Similarly, a significant trend in the proportion of individuals 117 
reporting injecting cocaine in the past six months was observed, rising sharply between 2015-16 and 2017-18. 118 
Significant increases were also notable when looking at those reporting injecting both heroin and cocaine and 119 
those reporting injecting heroin and cocaine together, often referred to as ‘snowballing’. Trends in needle 120 
reuse, injecting frequency and needle/syringe sharing also significantly increased over time, however high 121 
frequency injectors (i.e. those at greatest risk) and those who reported sharing needles/syringes typically 122 
account for less than 10% of the sample within each survey.  123 
In those who tested positive for HIV, the proportion injecting cocaine  or both heroin and cocaine  was 124 
considerably higher than among the HIV negative sample across the survey years with trends approaching 125 
significance. Rates of unprotected sex fluctuated but were notably highest when the outbreak was initially 126 
detected in 2015-16.  127 
Among HIV negative participants, needle and syringe coverage in the past six months fluctuated over time but, 128 
on average, around 70% reported having sourced sufficient sterile equipment to cover all of their injections. 129 
However, significant trend changes in the proportion of those who had recently been prescribed methadone 130 
were observed but remained relatively high across surveys.  131 
In those testing positive for HIV, significant trends in needle/syringe coverage per injection across surveys 132 
were observed. Notably where data was recorded, almost all the HIV positive cases participating in the 2017-133 
18 survey reported adequate provision. Recent methadone prescription rates were also high across surveys 134 
among those testing positive for HIV.    135 
In our first model, HIV infection was most strongly associated with cocaine injecting after accounting for other 136 
individual risk factors (Table 2). The association between high injecting frequency and HIV infection showed 137 
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borderline significance. We found no significant association between HIV infection and drinking above 138 
recommended weekly alcohol consumption guidelines or recent participation in unprotected sex.  139 
INSERT TABLE 2 140 
In our second model, HIV infection was most strongly associated with participation in more recent surveys 141 
(2015-16 and 2017-18), recent experience of homelessness  and a high number of incarcerations since first 142 
injecting drugs, after accounting for other environmental risk factors (Table 3). We also observed a gender 143 
association, with females significantly more likely to be HIV positive than males. Age was also significantly 144 
associated:  each year increase in age increased the likelihood of being HIV positive. We found no significant 145 
association between HIV infection and recent methadone prescribing or needle/syringe coverage.  146 
INSERT TABLE 3 147 
In our combined model, HIV infection was most strongly associated with history of cocaine injecting and 148 
participation in recent surveys after accounting for other indivdual and environmental risk factors (Table 4). 149 
Odds of HIV infection were also significantly higher for those with recent experience of homelessness and 150 
those with a high number of incarcerations since they first began injecting. Age also remained highly 151 
significantly associated with HIV. Increased risk of HIV among females in comparison to males showed 152 
borderline significance. We found no significant association between HIV infection and injecting frequency in 153 
our combined model.  154 
INSERT TABLE 4 155 
In sensitivity analysis, we included interaction effects between survey year, number of times in prison, 156 
homelessness, and cocaine injecting, in adjusted models (Appendix, page 1-3). The interaction coefficient in 157 
each model was not significant therefore it is unlikely that the strong association between cocaine injecting 158 
and HIV infection is dependent on survey year, incarceration history or recent experience of homelessness. In 159 
addition, we found no interaction effect between gender and survey year (Appendix, page 4) 160 
Discussion 161 
Prevalence of HIV infection among PWID in GGC increased markedly between 2011 and 2018. The highest 162 
rates were observed in Glasgow city centre where an outbreak of HIV among PWID was identified in 2015. 163 
Multivariate analysis highlighted that the strongest predictors of HIV infection among PWID in Glasgow were 164 
cocaine injecting and recent experience of homelessness.   165 
In the context of outbreaks of HIV among PWID reported globally in the last 10 years, this is the first to 166 
investigate the determinants of infection using an approach which combines both statistical power and robust 167 
survey methods applied consistently over time. NESI is one of only four equivalent national serial bio-168 
behavioural surveys of PWID worldwide and performs strongly in terms of coverage; typically recruiting 10-169 
15% of the Scottish PWID population each survey compared to less than 5% in studies conducted in England, 170 
Canada and Australia. In comparison to other recent epidemiological studies of HIV outbreaks among PWID 171 
which have typically relied on reactive sampling methods conducted over relatively short time periods,
5,6,17
 our 172 
study is the first to illustrate changes in HIV prevalence and risk factors among PWID over time and the impact 173 
of an outbreak on such trends. Moreover, the extensive bio-behavioural data available in NESI afforded us 174 
scope to consider a broad range of possible individual and environmental risk factors which few studies, to 175 
date, have been able to achieve.
15
  176 
Cocaine injection is a well established risk factor for HIV infection.
18
 The increasing trend toward cocaine 177 
injecting (50% in 2017-18) and its highly significant association with HIV infection among PWID in Glasgow is 178 
similar to recent shifts toward stimulant injecting observed among PWID elsewhere.
4
 Stimulants have a short 179 
half-life which is known to increase injecting frequency,
19
 and therefore BBV transmission risk, through 180 
reduced likelihood of using clean equipment at each injection.
20
 This risk is compounded if there is a lack of 181 




 Glasgow, however, has 182 
widespread availability of free-to-access harm reduction services, including NSP and OAT. At the onset of the 183 
outbreak, the GGC region was distributing in excess of one million needles and syringes per year;
21
 and there 184 
was a high self-reported uptake of injecting equipment among the HIV-positive cases (81% with 100%+ 185 
needle/syringe coverage). Uptake of OAT in these cases was also high (85% on OAT in the last six months) and 186 
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lacked association in our analysis, however this may not fully reflect breaks in treatment or optimised dosing 187 
of OAT during this period. This paradoxical scenario mirrors an outbreak of HIV among PWID in Vancouver 188 




Cocaine injecting may also impact on sexual behaviours which increase vulnerability to HIV transmission. Users 191 
report numerous high risk sexual behaviours that include inconsistent condom use, multiple sexual partners, 192 
and sex with other people who use drugs.
22
 Despite this established link, we found no significant association 193 
between HIV and unprotected sex in our sample. This could be due to a lack of statistical power or because 194 
sexual risk behaviour is strongly influenced by other individual or environmental factors we were unable to 195 
measure such as socio-economic status.
15
 Lack of association may also be due to the time frame we used for 196 
unprotected sex (last six months) and our lack of information on exactly when HIV infection was transmitted. 197 
The high proportion of females in our HIV positive sample (25%) mirrors findings from outbreaks in Dublin
5
 and 198 
Luxembourg,
4
 and their elevated risk of HIV infection in our model reinforces the need to acknowledge the 199 
potential risk of sexual transmission in the Glasgow outbreak and to tailor prevention strategies accordingly.  200 
In our study, cocaine injecting remained a highly significant predictor of HIV even after controlling for injecting 201 
frequency and unprotected sex. This suggests that there may be other unmeasured aspects of cocaine 202 
injecting that heighten the risk of HIV infection among PWID in Glasgow. Further research on the role of 203 
cocaine injecting facilitating and sustaining rapid transmission of HIV among PWID is merited. 204 
It is unclear as to why there has been such a huge recent shift toward powder cocaine injecting by PWID in 205 
Glasgow, a locality where heroin has dominated the illegal drug market for decades. One explanation may be a 206 
reported decline in heroin purity within the UK,
23
 research from Europe suggests cocaine purity is high at the 207 
moment –a characteristic which may have increased its attractiveness as an alternative to low quality heroin – 208 
and that ‘high risk’ cocaine use has increased in other European countries in recent years.
24
 Future research 209 
should urgently address the motivations and patterns of stimulant injecting among current or former opioid 210 
users, in particular those with experience of homelessness, to inform policy and practice responses. 211 
The strong link between homelessness and HIV infection provides additional evidence of the poor health 212 
outcomes and inequalities experienced by this population.
25
 Socioeconomic issues were also common across 213 
the other recent outbreaks of HIV among PWID, with homeless populations disproportionately affected in the 214 
majority of incidents.
4
 High prevalence of cocaine use among homeless populations has been documented 215 
previously.
26 
The majority of these studies link homelessness with crack cocaine injecting, yet in Glasgow it is 216 
powder cocaine which has become endemic among homeless drug injectors. 217 
Increases in homelessness in the UK have been observed since 2009.
27
 In Glasgow, this has occurred alongside 218 
an ageing cohort of PWID with significant co-morbidities and experience of exclusion. It is estimated that there 219 
are up to 500 individuals regularly injecting in public places in Glasgow city centre, many of whom are 220 
homeless.
28
 A needs assessment has highlighted the barriers to risk reduction behaviours in this population 221 
without addressing the existing social and addiction needs.
28
 The high prevalence of hepatitis C (>90%) 222 
amongst the HIV infected group also suggests that sharing of injecting equipment, either directly or indirectly, 223 
is extensive. Awareness of HIV risk among PWID may also have been sub-optimal compared to previous 224 
generations given the low prevalence which has existed since the 1980s. An increase in cocaine injecting and 225 
declining heroin purity alongside this is likely to be contributing to risk taking. Combined, these multiple 226 
factors create a high risk environment for drug-related harm in Glasgow,
29
 including rapid HIV transmission. 
 227 
As the first formal epidemiological investigation into Glasgow’s rapid HIV rise among PWID, this study has 228 
important implications for policy and practice. Primarily it will be of interest to policymakers focussed on 229 
reducing harms associated with drug use and achieving realistic public health goals such as HIV elimination.
30
 230 
An outbreak of HIV among PWID such as the one which has occurred in Glasgow threatens both these targets. 231 
Although our results are not directly generalisable, they should serve as a warning to countries with historically 232 
low HIV prevalence among PWID that things can change rapidly even with harm reduction services in place. 233 
Our findings also reinforce the importance of ongoing bio-behavioural surveillance initiatives among high risk 234 
groups in informing public health action. Studies such as NESI remain rare internationally despite the global 235 
health burden of HCV and HIV among PWID.  236 
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The response to the outbreak in Glasgow included an enhanced HIV model of care involving outreach nursing 237 
and community prescribing of anti-retroviral therapy (ART) that has engaged over 90% of the infected cohort 238 
in HIV treatment.
31
 The barriers to achieving full risk reduction, particularly in excluded populations, highlight 239 
the importance of HIV treatment as prevention (TasP). The multi-disciplinary response has also included: HIV 240 
education to those at-risk and service providers; increased availability of HIV testing; improved provision of 241 
injecting equipment services; and developments within addictions care, including work to introduce a drug 242 
consumption room and heroin assisted treatment service.
28
 This investigation highlights the importance of 243 
further work to review the addictions response to cocaine use in this population, including availability of 244 
psychosocial therapies and pharmacotherapy.  245 
There are challenges, however, in the implementation of the more innovative elements of this response. 246 
Maintaining the extended injecting equipment provision services (i.e. services which provide needles, syringes, 247 
foil, water, filters and other injecting equipment) was set back by the closure of the city’s largest NSP and 248 
whilst proposals to introduce a drug consumption room are approved locally and backed by the Scottish 249 
Parliament, sufficient legal exemptions have not been granted by the UK Government to allow it to operate.
28
 250 
The Heroin Assisted Treatment facility is not subject to the same legislative restrictions and is scheduled to 251 
open soon.   252 
This study also has a number of limitations which we acknowledge. Firstly, we were unable to determine when 253 
the participants in our sample acquired their HIV infection, therefore it is possible that risk factor data 254 
collected at the time they were surveyed had changed since they became infected. To mitigate this, we 255 
included risk factor data collected when the infection was first detected in our study only, either within or 256 
across surveys. Our risk factor data is also mainly derived from self-reported responses which may be subject 257 
to response bias despite our use of independent researchers. The credibility of self-reported behaviours by 258 
drug users has been validated elsewhere
32
 and we assume similar validity here. Our sample is biased towards 259 
those attending sites providing injecting equipment and PWID who do not regularly engage with such services 260 
may be underrepresented. However, evidence from GGC’s own needs assessment
28
 highlighted that PWID in 261 
Glasgow are regular attendees of city centre injecting equipment provision outlets. Lastly, although NESI 262 
includes a comprehensive range of individual and environmental risk factors, the potential for residual 263 
confounding in our study remains. For example, we were unable to determine changes in structure of injection 264 
networks of PWID in our sample over time, a variable which has been shown to impact HIV transmission.
33
 265 
After nearly three decades of effective harm reduction and prevention, Glasgow is currently experiencing one 266 
of Western Europe’s largest outbreaks of HIV among PWID. Lessons from Glasgow highlight that good 267 
availability of harm reduction services is not sufficient on its own to prevent outbreaks occurring among highly 268 
vulnerable populations. The risk environment in Glasgow in recent years has combined to develop a ‘perfect 269 
storm’ for rapid HIV transmission which has persisted for over three years despite a multi-disciplinary 270 
response. Our findings also demonstrate how critical robust surveillance, through regular HIV testing of high 271 
risk populations, is to ensure outbreaks are detected and rapid responses are informed by the best available 272 
evidence. 273 
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Table 1: Sample characteristics, risk behaviours, intervention coverage and HIV prevalence by survey year among PWID surveyed in Greater Glasgow 
and Clyde, 2011-2018.  




 2011-12 2013-14 2015-16 2017-18 pd,e 2011-14 2015-16 2017-18 pd,e 
Total participants recruited 955 905 930 825  12 24 46  
Overall sample following de-duplicationa 926 855 892 782  11 23 39  
          
Demographic and social characteristics          
Recruitment setting          
    Glasgow inner city centre, n (%) 86 (9) 259 (30) 191 (21) 206 (26) p<0.0001 * 13 (57) 25 (64) p=0.159 
    Rest of NHS Greater Glasgow & Clyde (GGC), n (%) 840 (91) 596 (70) 701 (79) 576 (74)  * 10 (43) 14 (36)  
    Missing, n (%) 0 (0) 0 (0) 0 (0) 0 (0)  0 (0) 0 (0) 0 (0)  
          
Gender          
   Male, n (%) 683 (74) 607 (71) 645 (72) 591 (76) p=0.317 * * 26 (67)  p=0.068 
   Female, n (%) 241 (26) 243 (28) 242 (27) 186 (24)  * * 13 (33)  
   Missing, n (%) 2 (0) 5 (1) 5 (1) 5 (1)  0 (0) 1 (3) 0 (0)  
          
Age          
   Mean (SD) 36 (6.16) 38 (7.08) 40 (7.13) 42 (6.97) p<0.0001 45 (3.31) 41 (6.95) 42 (7.41)   p=0.280 
   Missing, n (%) 2 (0) 1 (0) 0 (0) 6 (1)  0 (0) 0 (0) 0 (0)  
          
Homeless in the previous six months?          
   Yes, n (%) 183 (20) 236 (28) 177 (20) 199 (25) p=0.138 * 8 (35) 21 (54) p=1.000 
   No, n (%) 741 (80) 616 (72) 714 (80) 577 (74)  * 15 (65) 17 (44)  
   Missing, n (%) 2 (0) 3 (0) 1 (0) 6 (1)  0 (0) 0 (0) 1 (3)  
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Excessive alcohol consumption in the previous 12 
months? 
 
         
   Yes, n (%) 241 (26) 239 (28) 188 (21) 176 (23) p=0.016 5 (45) 4 (17) 8 (21) p=0.146 
   No, n (%) 683 (74) 615 (72) 683 (78) 592 (76)  6 (55) 17 (74) 29 (74)  
   Missing, n (%) 2 (0) 1 (0) 7 (1) 14 (2)  0 (0) 2 (9) 2 (5)  
          
Number of times in prison since first injected drugs          
    Low number (5 incarcerations or less) 556 (60) 505 (59) 537 (60) 444 (57) p=0.398 2 (18) 8 (35) 14 (36) p=0.359 
    High number (more than 5 incarcerations) 366 (40) 341 (40) 347 (39) 325 (42)  9 (82) 15 (43) 23 (59)  
    Missing, n (%) 4 (0) 9 (1) 8 (1) 13 (2)  0 (0) 0 (0) 2 (5)  
          
Risk behaviours          
Had unprotected sex in the previous six months?          
   Yes, n (%) N/A 420 (49) 374 (42) 284 (36) p<0.0001 3 (30) 12 (52) 9 (23) p=0.359 
   No, n (%) N/A 352 (41) 417 (47) 426 (55)  7 (70) 11 (48) 23 (59)  
   Missing, n (%) N/A 83 (10) 101 (11) 72 (9)  1 (9) 0 (0) 7 (18)  
          
Injected drugs in the previous six months?          
   Yes, n (%) 805 (87) 706 (83) 715 (80) 523 (67) p<0.0001 8 (73) 21 (91) 36 (92) p=0.093 
   No, n (%) 121 (13) 147 (72) 176 (20) 251 (32)  3 (27) 2 (9) 2 (5)  
   Missing, n (%) 0 (0) 2 (0) 1 (0) 8 (1)  0 (0) 0 (0) 1 (3)  
          
Injected drugs in the previous six monthsb,c          
    Heroin, n (%) 755 (94) 614 (87) 659 (92) 455 (87) p=0.003 5 (45) 16 (76) 28 (78) p=0.212 
    Cocaine, n (%) 129 (16)  151 (21) 166 (23) 250 (48) p<0.0001 4 (36) 19 (90) 30 (83) p=0.066 
    Heroin and cocaine, n (%) 97 (12) 87 (12) 127 (18) 192 (37) p<0.0001 1 (9) 15 (71) 22 (61) p=0.060 
    Heroin and cocaine together, n (%) 26 (3) 28 (4) 30 (4) 70 (13) p<0.0001 1 (9) 2 (10) 6 (17) p=0.613 
    Missing, n (%) 0 (0) 0 (0) 0 (0) 0 (0)  0 (0) 0 (0) 0 (0)  
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Average injecting frequency in the previous six 
monthsb 
 
         
    Low frequency (less than 4 times per day) 750 (93) 643 (91) 664 (93) 476 (91) p=0.325 7 (88) 12 (57) 31 (86) p=0.414 
    High frequency (4 or more times a day) 55 (7) 62 (9) 50 (7) 47 (9)  1 (13) 9 (43) 5 (14)  
    Missing, n (%) 0 (0) 3 (0) 2 (0) 0 (0)  0 (0) 0 (0) 0 (0)  
          
Shared needles/syringes in the previous six 
months?b 
 
         
    No, n (%) 749 (93) 653 (92) 659 (92) 465 (89) p=0.037 8 (100) 21 (100) 33 (92) p=0.065 
    Yes, n (%) 54 (7) 44 (6) 49 (7) 52 (10)  0 (0) 0 (0) 3 (8)  
    Missing, n (%) 2 (0) 9 (1) 7 (1) 6(1)  0 (0) 0 (0) 0 (0)  
          
Needle reuse in the previous six monthsb          
    Never, n (%) 525 (65) 369 (52) 364 (51) 140 (27) p<0.0001 5 (63) 8 (38) 9 (25) p=0.092 
    Yes, n (%) 275 (34) 337 (48) 348 (49) 293 (56)  3 (38) 13 (62) 20 (56)  
    Missing, n (%) 5 (1) 0 (0) 3 (0) 90 (17)  0 (0) 0 (0) 7 (19)  
          
Intervention coverage          
Syringe coverage in the previous six monthsb          
    <100%, n (%) 214 (27) 105 (15) 239 (33) 125 (24) p=0.111 2 (25) 8 (38) 2 (6) p=0.012 
    100% +, n (%) 586 (73) 594 (84) 462 (65) 392 (75)  6 (75) 13 (62) 33 (92)  
    Missing, n (%) 5 (1) 7 (1) 14 (2) 6 (1)  0 (0) 0 (0) 2=1 (3)  
          
Prescribed methadone in the previous six months?          
   Yes, n (%) 814 (88) 602 (70) 709 (80) 627 (80) p=0.016 11 (100) 16 (70) 31 (80) p=0.365 
   No, n (%) 110 (12) 252 (30) 183 (21) 147 (19)  0 (0) 7 (30) 7 (18)  
   Missing, n (%) 2 (0) 1 (0) 0 (0) 8 (1)  0 (0) 0 (0) 1 (3)  
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BBV prevalence          
Valid DBS tests for HCV 926 853 892 822  11 23 39  
          
HCV antibody prevalence, n (%) 584 (63) 592 (69) 575 (65) 520 (67) p=0.606 10 (91) 22 (96) 37 (95) p=0.981 
    Glasgow inner city centre, n (%) 65 (76) 199 (77) 124 (65) 156 (76) p=0.452 4 (100) 13 (100) 25 (100) p=1.000 
    Rest of NHS GGC, n (%) 519 (62) 393 (66) 451 (64) 364 (63) p=0.612 6 (86) 9 (90) 12 (86) p=0.691 
          
ALL PARTICIPANTS          
 2011-12 2013-14 2015-16 2017-18      
Valid DBS tests for HIV 927 905 915 821      
          
HIV antibody prevalence, n (%) 1 (0.1) 10 (1.1) 23 (2.5) 39 (4.8) p<0.0001     
    Glasgow inner city centre, n (%) 1 (1.1) 3 (1.1) 13 (6.3) 25 (10.8) p<0.0001     
    Rest of NHS GGC, n (%) 0 (0) 7 (1.1) 10 (1.2) 14 (2.4) p<0.0001     
 
a Denominators do not always match overall sample totals due to missing or insufficient data 
b Among injectors who report injecting drugs in the last six months 
c Percentages will add up to more than 100% as individuals may have reported use of more than one drug 
d Chi-square test for trend for categorical variables 
e one-way ANOVA test for continuous variables 
* Data suppressed to minimise risk of deductive disclosure 
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Table 2: Odds ratios (ORs), Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for individual factors associated HIV infection among PWID in 
Greater Glasgow and Clyde, 2011-2018. 
    Adjusted model overall sample (n = 2591) 
 
HIV+, n (%)* OR (95% CI) p AOR (95% CI) p 
Excessive alcohol consumption in the last 12 months 
 
  
       No 48 (74) 1.0 
 
1.0 
     Yes 17 (26) 1.1 (0.6-1.9) 0.78 0.8 (0.5-1.5) 0.49 
Had unprotected sex in the last six months 
 
  
       No 41 (59) 1.0 
 
1.0 
     Yes 21 (30) 0.6 (0.3-1.0) 0.044 0.6 (0.4-1.1) 0.090 
   Not recorded 7 (10) 0.2 (0.1-0.4) <0.0001 0.2 (0.1-0.5) 0.00030 
Injected cocaine in the last six months    
       No 19 (20) 1.0 
 
1.0 
     Yes 49 (80) 11.3 (6.6-19.4) <0.0001 9.0 (5.2-15.8) <0.001 
Average injecting frequency in the last six months    
       Low frequency (4 times per day or less), n (%) 55 (80) 1.0 
 
1.0 
     High frequency (4 or more times a day), n (%) 14 (20) 4.0 (2.2-7.3) <0.0001 1.8 (0.9-3.7) 0.083 
      *not all values add up to 69 due to missing data 









Table 3: Odds ratios (ORs), Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for environmental factors associated HIV infection among PWID in 
Greater Glasgow and Clyde, 2011-2018. 
    Adjusted model overall sample (n = 2526) 
 




       2011-12 and 2013-14 11 (16) 1.0 
 
1.0 
     2015-16 and 2017-18 58 (84) 6.0 (3.1-11.4) <0.0001 5.8 (2.9-11.3) <0.0001 
Age     
      Age (Per Year Increase) 69 (100) 1.1 (1.0-1.1) <0.0001 1.1 (1.0-1.1) 0.0037 
Gender     
      Male 51 (75) 1.0  1.0 
     Female 17 (25) 0.9 (0.5-1.6) 0.73 1.9 (1.0-3.7) 0.081 
Homeless in the last six months     
      No 31 (46) 1.0  1.0 
     Yes 37 (54) 4.2 (2.6-6.8) <0.0001 4.1 (2.5-6.9) <0.0001 
Number of times in prison since first injected drugs 
 
  
       Low number (5 incarcerations or less) 23 (34) 1.0 
 
1.0 
     High number (more than 5 incarcerations) 44 (66) 3.1 (1.9-5.2) <0.0001 2.9 (1.7-5.1) 0.00014 
Prescribed methadone in the last six months 
 
   
      No 10 (15) 1.0  1.0 
     Yes 58 (85) 1.3 (0.7-2.6) 0.41 0.7 (0.3-1.5) 0.40 
Syringe coverage in the in the last six months    
       <100% 11 (16) 1.0 
 
1.0 
     100%+ 48 (71) 1.4 (0.7-2.6) 0.36 1.6 (0.8-3.0) 0.19 
    Did not inject in the last six months 9 (13) 0.6 (0.2-1.6) 0.34 0.5 (0.2-1.3) 0.17 
      *not all values add up to 69 due to missing data 




Table 4: Odds ratios (ORs), Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for individual and environmental factors associated with HIV 
infection among PWID in Greater Glasgow and Clyde, 2011-2018. 
    Adjusted model overall sample (n = 2586) 
 
HIV+, n (%)* OR (95% CI) p AOR (95% CI) p 
NESI survey     
       2011-12 and 2013-14 11 (16) 1.0 
 
1.0 
     2015-16 and 2017-18 58 (84) 6.0 (3.1-11.4) <0.0001 3.4 (1.7-6.7) 0.00052 
Age      
      Age (Per Year Increase) 69 (100) 1.1 (1.0-1.1) <0.0001 1.1 (1.0-1.1) 0.0016 
Gender      
      Male 51 (75) 1.0  1.0 
     Female 17 (25) 0.9 (0.5-1.6) 0.73 1.7 (0.9-3.2) 0.083 
Homeless in the last six months      
      No 31 (46) 1.0  1.0 
     Yes 37 (54) 4.2 (2.6-6.8) <0.0001 3.0 (1.7-5.0) <0.0001 
Number of times in prison since first injected drugs     
       Low number (5 incarcerations or less) 23 (34) 1.0 
 
1.0 
     High number (more than 5 incarcerations) 44 (66) 3.1 (1.9-5.2) <0.0001 2.1 (1.2-3.7) 0.0098 
Injected cocaine in the last six months     
       No 19 (20) 1.0 
 
1.0 
     Yes 49 (80) 11.3 (6.6-19.4) <0.0001 6.7 (3.8-12.1) <0.0001 
Average injecting frequency in the last six months     
       Low frequency (less than 4 times per day) 47 (77) 1.0 
 
1.0 
     High frequency (4 or more times a day) 14 (23) 4.0 (2.2-7.3) <0.0001 1.7 (0.8-3.4) 0.14 
      *not all values add up to 69 due to missing data 
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